218 related articles for article (PubMed ID: 22180196)
1. Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy.
So C; Kirby KA; Mehta K; Hoffman RM; Powell AA; Freedland SJ; Sirovich B; Yano EM; Walter LC
J Gen Intern Med; 2012 Jun; 27(6):653-60. PubMed ID: 22180196
[TBL] [Abstract][Full Text] [Related]
2. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
[TBL] [Abstract][Full Text] [Related]
3. PSA screening among elderly men with limited life expectancies.
Walter LC; Bertenthal D; Lindquist K; Konety BR
JAMA; 2006 Nov; 296(19):2336-42. PubMed ID: 17105796
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
5. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.
Drazer MW; Huo D; Schonberg MA; Razmaria A; Eggener SE
J Clin Oncol; 2011 May; 29(13):1736-43. PubMed ID: 21444863
[TBL] [Abstract][Full Text] [Related]
6. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare.
Bynum J; Song Y; Fisher E
J Am Geriatr Soc; 2010 Apr; 58(4):674-80. PubMed ID: 20345867
[TBL] [Abstract][Full Text] [Related]
7. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
8. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
9. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
10. Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines.
O'Neil B; Martin C; Kapron A; Flynn M; Kawamoto K; Cooney KA
Cancer Epidemiol; 2018 Oct; 56():112-117. PubMed ID: 30130683
[TBL] [Abstract][Full Text] [Related]
11. Primary care providers' perspectives on discontinuing prostate cancer screening.
Pollack CE; Platz EA; Bhavsar NA; Noronha G; Green GE; Chen S; Carter HB
Cancer; 2012 Nov; 118(22):5518-24. PubMed ID: 22517310
[TBL] [Abstract][Full Text] [Related]
12. Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.
Radomski TR; Huang Y; Park SY; Sileanu FE; Thorpe CT; Thorpe JM; Fine MJ; Gellad WF
J Am Geriatr Soc; 2019 Sep; 67(9):1922-1927. PubMed ID: 31276198
[TBL] [Abstract][Full Text] [Related]
13. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
14. Are there regional tendencies toward controversial screening practices? A study of prostate and breast cancer screening in a Medicare population.
Raffin E; Onega T; Bynum J; Austin A; Carmichael D; Bronner K; Goodney P; Hyams ES
Cancer Epidemiol; 2017 Oct; 50(Pt A):68-75. PubMed ID: 28822325
[TBL] [Abstract][Full Text] [Related]
15. The Aging Mountaineer: PSA screening in older men--of value or should we skip this test?
Crigger C; Salkini M; Zaslau S
W V Med J; 2016; 112(3):36-40. PubMed ID: 27301153
[TBL] [Abstract][Full Text] [Related]
16. Reducing PSA-Based Prostate Cancer Screening in Men Aged 75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support.
Shelton JB; Ochotorena L; Bennett C; Shekelle P; Kwan L; Skolarus T; Goldzweig C
J Gen Intern Med; 2015 Aug; 30(8):1133-9. PubMed ID: 25740462
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists.
Fowler FJ; Bin L; Collins MM; Roberts RG; Oesterling JE; Wasson JH; Barry MJ
Am J Med; 1998 Jun; 104(6):526-32. PubMed ID: 9674714
[TBL] [Abstract][Full Text] [Related]
18. Durable improvements in prostate cancer screening from online spaced education a randomized controlled trial.
Kerfoot BP; Lawler EV; Sokolovskaya G; Gagnon D; Conlin PR
Am J Prev Med; 2010 Nov; 39(5):472-8. PubMed ID: 20965387
[TBL] [Abstract][Full Text] [Related]
19. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.
Hoffman KE; Nguyen PL; Ng AK; D'Amico AV
J Urol; 2010 May; 183(5):1798-802. PubMed ID: 20299039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
